Richard W. Pascoe

Richard W. Pascoe, listed as chief executive, has filed trades across 4 companies (mainly through SEC (Form 4)), most often in Somaxon Pharmaceuticals, Inc., Zevra Therapeutics, Inc. and Seelos Therapeutics, Inc. We count 55 filings; the first trade dates from 28 November 2008 and the latest from 9 March 2023.

The open-market side counts 19 purchases for €273k alongside 11 sales for €756k. Sales outweigh purchases by €483k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Besides market trades, the filings include 20 share grants and 3 option exercises. So far in 2023, the count stands at 2 purchases and no sales.

A typical purchase (the median) is worth €8,301. On 12 out of 14 purchases, another insider of the same company was buying within the same 30 days. Purchases made close together by different insiders form what is called a cluster.

The latest filing, published on 13 March 2023, reports an open-market purchase of €40k in Zevra Therapeutics, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. US insiders must file a Form 4 within two business days of a trade. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.